Clesrovimab · Medicine question

How does clesrovimab prevent RSV from entering cells?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Clesrovimab provides passive immunity by binding to a conserved epitope at antigenic site IV on the RSV outer membrane fusion (F) protein, preventing viral entry into cells.

Sources for this answer

ENFLONSIA® 105 mg solution for injection in pre-filled syringeMerck Sharp & Dohme (UK) Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 2Document updated 22 June 2026

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

What is ENFLONSIA (clesrovimab) used to prevent, and in which infants?Have the safety and efficacy of clesrovimab been established in children aged 1 to 18 years?How much polysorbate 80 does an ENFLONSIA (clesrovimab) pre-filled syringe contain?What are the most frequent side effects of clesrovimab in infants?What should ENFLONSIA (clesrovimab) solution for injection look like?Where and by what route is ENFLONSIA (clesrovimab) injected?

loading page…

Answer

Sources for this answer

More questions about Clesrovimab

Answer

Sources for this answer

More questions about Clesrovimab

Clesrovimab

More clinical questions?